IMIPENEM AND CILASTATIN FOR INJECTION, USP POWDER FOR SOLUTION
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
10-03-2023
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
CILASTATIN (CILASTATIN SODIUM); IMIPENEM
Fáanlegur frá:
STERIMAX INC
ATC númer:
J01DH51
INN (Alþjóðlegt nafn):
IMIPENEM AND CILASTATIN
Skammtar:
250MG; 250MG
Lyfjaform:
POWDER FOR SOLUTION
Samsetning:
CILASTATIN (CILASTATIN SODIUM) 250MG; IMIPENEM 250MG
Stjórnsýsluleið:
INTRAVENOUS
Einingar í pakka:
100
Gerð lyfseðils:
Prescription
Lækningarsvæði:
CARBAPENEMS
Vörulýsing:
Active ingredient group (AIG) number: 0218820002; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
2023-03-10
Vara einkenni
Page 1 of 50
PRODUCT MONOGRAPH
PR
IMIPENEM AND CILASTATIN FOR INJECTION, USP
Imipenem 250 mg and Cilastatin 250 mg (as cilastatin sodium) per vial
Imipenem 500 mg and Cilastatin 500 mg (as cilastatin sodium) per vial
Sterile Powder for Intravenous Infusion
ANTIBIOTIC
SteriMax Inc.
2770 Portland Drive
Oakville, ON
L6H 6R4
Control No.: 271444
Date of Preparation:
MAR 10, 2023
Page 2 of 50
TABLE OF CONTENTS
PRODUCT MONOGRAPH
..........................................................................................................
1
THERAPEUTIC
CLASSIFICATION
...........................................................................................................
3
INDICATIONS
AND
CLINICAL
USE
.........................................................................................................
3
CONTRAINDICATIONS
..............................................................................................................................
5
WARNINGS
..................................................................................................................................................
5
PRECAUTIONS
............................................................................................................................................
6
OVERDOSAGE
...........................................................................................................................................
12
DOSAGE
AND
ADMINISTRATION
.........................................................................................................
12
PHARMACEUTICAL
INFORMATION
....................................................................................................
16
COMPATIBILITY
AND
STABILITY
........................................................................................................
17
AVAILABILITY
OF
DOSAGE
FORMS
....................................................................................................
18
STORAGE
..................................................................................
Lestu allt skjalið
